Pharmacokinetics of etodolac in patients with stable juvenile rheumatoid arthritis

Clinical Therapeutics

Volumn 21, Issue 10, 1999, Pages 1715-1724

  Boni, Joseph P ^a,c   Korth Bradley, Joan M ^a   Martin, Patrick ^a   Simcoe, Donna K ^a   Richards, Lyette S ^a   Rennebohm, Robert ^b   Walson, Philip D ^b  

^a WYETH AYERST RESEARCH   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c NONE   (United States)

Author keywords

Children; Etodolac; Juvenile rheumatoid arthritis; Nonsteroidal anti inflammatory drug; Pharmacokinetics

Indexed keywords

ETODOLAC;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; MEAN RESIDENCE TIME; ORAL DRUG ADMINISTRATION;

EID: 0032716428     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80050-2     Document Type: Article

References (16)

1. Cayen MN, Kraml M, Ferdinandi ES, et al. The metabolic disposition of etodolac in rats, dogs, and man. Drug Metab Rev. 1981;12:339-362.
2. 14C-etodolac in man. Xenobiotica. 1986; 16:153-166.
3. Dey M, Enever R, Marino M, et al. Sustained-release etodolac bioavailability and dose proportionality: Correlation between in vivo and in vitro performance. Int J Pharm. 1989;49:121-128.
4. Kauffman R, Nelson M. Effect of age on ibuprofen pharmacokinetics and antipyretic response. J Pediatr. 1992;121:969-973.
5. Haapasaari J, Wuolijoki E, Ylijoki J. Treatment of juvenile rheumatoid arthritis with diclofenac sodium. Scand J Rheumatol. 1983;12:325-330.
6. Halle F, Marfil F, Sioufi A, et al. Pharmacokinetics of pirprofen in children with juvenile chronic arthritis. Eur J Drug Metab Pharmacokinet. 1991;16:29-34.
7. Scaroni C, Mazzoni PL, D'Amico E, et al. Pharmacokinetics of oral and rectal flurbiprofen in children. Eur J Clin Pharmacol. 1984;27:367-369.
8. Forrest JB, Heitlinger EL, Revell S. Ketorolac for postoperative pain management in children. Drug Saf. 1997;16:309-329.
9. Walson P, Mortensen ME. Pharmacokinetics of common analgesic anti-nflammatories and antipyretics in children. Clin Pharmacokinet. 1989;17(Suppl 1):116-137.
10. Levinson JE, Baum J, Brewer E Jr, et al. Comparison of tolmetin sodium and aspirin in the treatment of juvenile rheumatoid arthritis. J Pediatr. 1977;91:799-804.
11. Mäkelä AL, Olkkola KT, Mattila MJ. Steady state pharmacokinetics of piroxicam in children with rheumatic diseases. Eur J Clin Pharmacol. 1991;41:79-81.
12. Cosyns L, Spain M, Kraml M. Sensitive high-performance liquid chromatographic method for the determination of etodolac in serum. J Pharm Sci 1983;72:275-277.
13. Jusko WJ. Guidelines for collection and analysis of pharmacokinetic data. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring. 3rd ed. Spokane, Wash: Applied Therapeutics; 1992:1-43.
14. Lima JJ, MacKichan JJ, Libertin N, Sabino J. Influence of volume shifts on drug binding during equilibrium dialysis: Correction and attenuation. J Pharmacokinet Biopharm. 1983;11:483-498.
15. SAS Institute. SAS/STAT User's Guide. 4th ed. Cary, NC: SAS Institute; 1990.
16. Noe DA, Rock RC, eds. Laboratory Medicine: The Selection and Interpretation of Clinical Laboratory Studies. Baltimore, Md: Williams & Wilkins; 1994.